EyeGate Pharmaceuticals Inc.

35.30
0.00 (0.01%)
At close: Mar 28, 2025, 3:59 PM
35.48
0.50%
After-hours: Mar 28, 2025, 04:05 PM EDT

EyeGate Pharmaceuticals Statistics

Share Statistics

EyeGate Pharmaceuticals has 760.93K shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding 760.93K
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Institutions (%) 8.45%
Shares Floating -
Failed to Deliver (FTD) Shares 263
FTD / Avg. Volume 24.47%

Short Selling Information

The latest short interest is 0, so 0% of the outstanding shares have been sold short.

Short Interest 0
Short % of Shares Out 0%
Short % of Float 0%
Short Ratio (days to cover) 0

Valuation Ratios

The PE ratio is 17.54 and the forward PE ratio is null. EyeGate Pharmaceuticals's PEG ratio is 0.

PE Ratio 17.54
Forward PE n/a
PS Ratio 8.46
Forward PS 48
PB Ratio 5.26
P/FCF Ratio 15.84
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for EyeGate Pharmaceuticals Inc..

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.94, with a Debt / Equity ratio of 0.

Current Ratio 4.94
Quick Ratio 4.94
Debt / Equity 0
Total Debt / Capitalization 0.22
Cash Flow / Debt 149.71
Interest Coverage -122.89

Financial Efficiency

Return on equity (ROE) is 0.3% and return on capital (ROIC) is 13.93%.

Return on Equity (ROE) 0.3%
Return on Assets (ROA) 0.21%
Return on Capital (ROIC) 13.93%
Revenue Per Employee $1,144,285.71
Profits Per Employee $551,767.36
Employee Count 14
Asset Turnover 0.44
Inventory Turnover n/a

Taxes

Income Tax -2.07M
Effective Tax Rate -0.36

Stock Price Statistics

The stock price has increased by -1.26% in the last 52 weeks. The beta is 0.35, so EyeGate Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.35
52-Week Price Change -1.26%
50-Day Moving Average 35.36
200-Day Moving Average 35.86
Relative Strength Index (RSI) 51.81
Average Volume (20 Days) 1.07K

Income Statement

In the last 12 months, EyeGate Pharmaceuticals had revenue of 16.02M and earned 7.72M in profits. Earnings per share was 1.99.

Revenue 16.02M
Gross Profit 16.02M
Operating Income 2.64M
Net Income 7.72M
EBITDA 0
EBIT 2.64M
Earnings Per Share (EPS) 1.99
Full Income Statement

Balance Sheet

The company has 3.79M in cash and 57.17K in debt, giving a net cash position of 3.74M.

Cash & Cash Equivalents 3.79M
Total Debt 57.17K
Net Cash 3.74M
Retained Earnings -143.38M
Total Assets 38.51M
Working Capital 28.12M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.56M and capital expenditures -6.26K, giving a free cash flow of 8.55M.

Operating Cash Flow 8.56M
Capital Expenditures -6.26K
Free Cash Flow 8.55M
FCF Per Share 2.21
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of 16.45% and 48.22%.

Gross Margin 100%
Operating Margin 16.45%
Pretax Margin 35.33%
Profit Margin 48.22%
EBITDA Margin n/a
EBIT Margin 16.45%
FCF Margin 53.39%

Dividends & Yields

EYEG pays an annual dividend of $2.26, which amounts to a dividend yield of 5.89%.

Dividend Per Share $2.26
Dividend Yield 5.89%
Dividend Growth (YoY) -4.54%
Payout Ratio -127.66%
Earnings Yield 5.64%
FCF Yield 31.84%
Dividend Details

Analyst Forecast

Currently there are no analyst rating for EYEG.

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Stock Forecasts

Stock Splits

The last stock split was on Aug 30, 2019. It was a backward split with a ratio of 1:15.

Last Split Date Aug 30, 2019
Split Type backward
Split Ratio 1:15

Scores

Altman Z-Score -3.28
Piotroski F-Score 4